Docteur LOIC LE DANTEC

Publications académiques en France

Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.

• New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case–control MISSIL study

  2022

  ArticleRheumatology

• Incidence of paradoxical reactions in patients treated with tocilizumab for rheumatoid arthritis: Data from the French registry REGATE

  2018

  ArticleJoint Bone Spine

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

• HOPITAL DE RIAUMONT

  Rue D'ENTRE DEUX MONTS, 62800 Liévin

  ☎ 0321448080Hospitalier🏥 Voir cet établissement

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Articles de presse (1)

Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).

• La polyclinique d’Hénin-Beaumont ouvre un centre médico-chirurgical dédié aux maladies du dos - La Voix du Nord

  📰 La Voix du Nord · 22/07/2020

  <a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPRG1BNEZYVFVGeXRub3REbnVPNjNDU1pCcDNQNmhHMEhELUR3bFB0d2RucXhkWlEzWE4wMG9oS0RkN2FSSWVqVkp4ZE5rZ3R6dmJBaG9SZHRfbU9wVUVXU3Z0NEl5OGRFS2VmVTczTDZwWnpGRk12WS1Fc1Q5V0lhYnBLUXJGWHVGNWVFd2xueTJyTnVaNnlvOUlHQ19KOFJYV3dPRDZvUjBqVzhzSkpBUzZXZ1hRR1ZkSn

Top publications · les plus citées

• 1

  Peripheral pyogenic arthritis. A study of one hundred seventy-nine cases

  Revue du rhumatisme (English ed.) · 1996

  📚 90 citations🎯 RCR 4.18Top 10% NIH
• 2

  Incidence of paradoxical reactions in patients treated with tocilizumab for rheumatoid arthritis: Data from the French registry REGATE

  Joint bone spine · 2018

  📚 12 citations🩺 Clinique
• 3

  New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case-control MISSIL study

  Rheumatology (Oxford, England) · 2022

  📚 8 citations

  Lire l'abstract Crossref ↓

  Abstract Objectives To describe new-onset IBD (new IBD) in patients treated with IL-17 inhibitors (IL-17i), to assess their incidence and to identify their risk factors in real life. Methods A French national registry (MISSIL) aimed to report all cases of new IBD in patients treated with IL-17i from January 2016 to December 2019. Using the estimated number of patients treated by IL-17 in France during the study period, the annual incidence rates of new IBD was reported in IL-17i-treated patients. A case–control study was performed with two controls per new IBD case matched by gender, age and underlying inflammatory disease. Results Thirty-one cases of new IBD under IL-17i were collected: 27 patients treated for spondyloarthritis and four patients for psoriasis. All were observed with secukinumab (SEK). The median time to onset of new IBD symptoms was 4.0 (1.5–7.5) months. SEK was discontinued in all patients. The evolution was favourable with complete resolution (17/31), improvement (7/31) or stabilization (5/31). Two patients died: one due to a massive myocardial infarction and one due to post-colectomy complications. The incidence of new IBD decreased from 0.69/100 patient-years [PY] (7/1010) in 2016 to 0.08/100 PY (6/7951) in 2019. No previous treatment with etanercept (odds ratio [OR] = 0.33, 95% CI: 0.14–0.80, P = 0.014) and low number of previous biologic therapies (OR = 0.67, 95% CI: 0.47, 0.94, P = 0.021) were significantly associated with new IBD. Conclusion The incidence of new IBD was low and decreased from 2016 to 2019. The outcome was favourable in 24 out of 31 patients, but two patients died.

Publications scientifiques (3) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche